Cancer Research Cell Death Mechanisms and Cancer Therapy  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Zein, R. A.
Right arrow Articles by Spitz, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Zein, R. A.
Right arrow Articles by Spitz, M. R.
[Cancer Research 66, 6449-6456, June 15, 2006]
© 2006 American Association for Cancer Research


Epidemiology and Prevention

Cytokinesis-Blocked Micronucleus Assay as a Novel Biomarker for Lung Cancer Risk

Randa A. El-Zein, Matthew B. Schabath, Carol J. Etzel, Mirtha S. Lopez, Jamey D. Franklin and Margaret R. Spitz

Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Randa A. El-Zein, Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Unit 1340, P.O. Box 301439, Houston, TX 77030-1439. Phone: 713-745-2539; Fax: 713-792-9568; E-mail: relzein{at}mdanderson.org.

In this case-control study, we modified the cytokinesis-block micronucleus (CBMN) assay, an established biomarker for genomic instability, to evaluate susceptibility to the nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by measuring the frequency of NNK-induced chromosomal damage endpoints (micronuclei, nucleoplasmic bridges, and nuclear buds) per 1,000 binucleated lymphocytes. Spontaneous and NNK-induced chromosomal damage were significantly higher in lung cancer patients compared with controls. Forty-seven percent of cases (versus 12% of controls) had ≥4 spontaneous micronuclei, 66% of cases (and no controls) had ≥4 spontaneous nucleoplasmic bridges, and 25% of cases (versus 5% of controls) had ≥1 spontaneous nuclear bud (P < 0.001). Similarly, 40% of cases (versus 6% of the controls) had ≥5 NNK-induced micronuclei, 89% of cases (and no controls) had ≥6 induced nucleoplasmic bridges, and 23% of cases (versus 2% of controls) had ≥2 induced nuclear buds (P < 0.001). When analyzed on a continuous scale, spontaneous micronuclei, nucleoplasmic bridges, and nuclear buds were associated with 2-, 29-, and 6-fold increases in cancer risk, respectively. Similarly, NNK-induced risks were 2.3-, 45.5-, and 10-fold, respectively. We evaluated the use of CBMN assay to predict cancer risk based on the numbers of micronuclei, nucleoplasmic bridges, and nuclear buds defined by percentile cut points in controls. Probabilities of being a cancer patient were 96%, 98%, and 100% when using the 95th percentiles of spontaneous and NNK-induced micronuclei, nucleoplasmic bridges, and nuclear buds, respectively. Our study indicates that the CBMN assay is extremely sensitive to NNK-induced genetic damage and may serve as a strong predictor of lung cancer risk. (Cancer Res 2006; 66(12): 6449-56)




This article has been cited by other articles:


Home page
MutagenesisHome page
J. Wu, G. H. Lyons, R. D. Graham, and M. F. Fenech
The effect of selenium, as selenomethionine, on genome stability and cytotoxicity in human lymphocytes measured using the cytokinesis-block micronucleus cytome assay
Mutagenesis, May 1, 2009; 24(3): 225 - 232.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
B. Benassi-Evans, P. M. Clifton, M. Noakes, J. B. Keogh, and M. Fenech
High protein-high red meat versus high carbohydrate weight loss diets do not differ in effect on genome stability and cell death in lymphocytes of overweight men
Mutagenesis, May 1, 2009; 24(3): 271 - 277.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. A. El-Zein, M. Fenech, M. S. Lopez, M. R. Spitz, and C. J. Etzel
Cytokinesis-Blocked Micronucleus Cytome Assay Biomarkers Identify Lung Cancer Cases Amongst Smokers
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1111 - 1119.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
B. Benassi, R. LeLeu, T. Bird, P. Clifton, and M. Fenech
Cytokinesis-Block Micronucleus Cytome Assays for the Determination of Genotoxicity and Cytotoxicity of Cecal Water in Rats and Fecal Water in Humans
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2676 - 2680.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
A. Zijno, F. Saini, and R. Crebelli
Suitability of cryopreserved isolated lymphocytes for the analysis of micronuclei with the cytokinesis-block method
Mutagenesis, September 1, 2007; 22(5): 311 - 315.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.